DC-LC3in-D5

• Description:

  DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC50 of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination researchs in cancer through inhibiting autophagy[1].

• UNSPSC:

  12352005

• Target:

  Atg8/LC3; Autophagy

• Type:

  Reference compound

• Related Pathways:

  Autophagy

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/dc-lc3in-d5.html

• Purity:

  98.62

• Solubility:

  DMSO : 35.71 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1/C (C (CC (C2=C (Cl) C (Cl) =CC=C2) C1) =O) =C/NCCN3CCOCC3

• Molecular Formula:

  C19H22Cl2N2O3

• Molecular Weight:

  397.30

• References & Citations:

  [1]Shijie Fan, et al. Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein. Angew Chem Int Ed Engl. 2021 Dec 6;60 (50) :26105-26114.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2868312-73-4